SAREPTA THERAPEUTICS INC (SRPT)
US8036071004 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 427.29M | 428.43M | 966.80M | 2.12B | 1.50B | |||
| Marketable Securities | 963.45M | 1.25B | 1.02B | 0.00 | 435.90M | |||
| Receivables | 419.38M | 439.71M | 259.70M | 171.60M | 138.60M | |||
| Inventories | 373.53M | 322.86M | 204.00M | 186.20M | 232.00M | |||
| Other Current Assets | 281.21M | 140.52M | 104.80M | 130.40M | 176.10M | |||
| Total Current Assets | 2.46B | 2.58B | 2.56B | 2.60B | 2.49B | |||
| Non-Current Assets | ||||||||
| PPE Net | 375.57M | 357.11M | 245.00M | 236.70M | 282.20M | |||
| Investments And Advances | 41.38M | 6.53M | 31.30M | 34.90M | 38.80M | |||
| Intangibles | 28.93M | 29.62M | 7.60M | 14.20M | 13.60M | |||
| Other Non-Current Assets | 313.64M | 291.99M | 286.60M | 258.10M | 164.90M | |||
| Total Non-Current Assets | 759.52M | 685.25M | 570.50M | 543.90M | 499.50M | |||
| TOTAL ASSETS | 3.22B | 3.26B | 3.13B | 3.15B | 2.98B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 105.59M | 105.48M | N/A | N/A | N/A | |||
| Accrued Expenses | 167.81M | 219.00M | 353.20M | 224.60M | 171.90M | |||
| Accounts Payable | 91.54M | 164.92M | 95.90M | 76.70M | 111.10M | |||
| Other Current Liabilities | 243.78M | 164.26M | 170.50M | 151.40M | 133.10M | |||
| Total Current Liabilities | 608.71M | 653.66M | 619.60M | 452.70M | 416.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 1.13B | 1.13B | 1.54B | 1.10B | 992.50M | |||
| Other Non-Current Liabilities | 520.82M | 619.07M | 579.50M | 670.40M | 814.40M | |||
| Total Non-Current Liabilities | 1.65B | 1.75B | 2.12B | 1.77B | 1.81B | |||
| TOTAL LIABILITIES | 2.26B | 2.41B | 2.74B | 2.22B | 2.22B | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -4.41B | -4.45B | -3.91B | -3.21B | -2.85B | |||
| Additional Paid In Capital | 5.37B | 5.30B | 4.30B | 4.13B | 3.61B | |||
| Common Shares | 9.00K | 9.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -691.00K | 918.00K | -1.70M | 0.00 | 0.00 | |||
| Shares Outstanding | 94.49M | 93.73M | 88.00M | 87.10M | 79.40M | |||
| Tangible Book Value per Share | 9.87 | 8.85 | 4.29 | 10.49 | 9.42 | |||
| Total Shareholders' Equity | 961.19M | 859.34M | 385.00M | 928.00M | 761.80M | |||
| TOTAL LIABILITIES AND EQUITY | 3.22B | 3.26B | 3.13B | 3.15B | 2.98B | |||
| Statistics | ||||||||
| Debt/Equity | 1.18 | 1.32 | 4.01 | 1.18 | 1.30 | |||
| Current Ratio | 4.05 | 3.95 | 4.13 | 5.75 | 5.97 | |||
| Return On Assets (ROA) | 0.53% | -16.42% | -22.49% | -13.30% | -18.56% | |||
| Return On Equity (ROE) | 1.77% | -62.37% | -182.73% | -45.13% | -72.74% | |||
All data in USD